Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00287547 · ClinicalTrials.gov registry record · Phase 2
Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris
A Phase 2 study of Psoriasis Vulgaris, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 144
- Enrollment target
- 10
- Study locations
NCT00287547 is a Phase 2 study of Psoriasis Vulgaris that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 144 participants, above the 68-participant average among 6 other Psoriasis Vulgaris trials with a reported enrollment target (112% higher). The trial reports 10 study locations across 10 states.
The verdict
NCT00287547, a Phase 2 study of Psoriasis Vulgaris, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 144 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to assess the safety, pharmacokinetics and clinical activity and immunogenicity of BMS-188667 (CTLA4Ig) in subjects with psoriasis vulgaris
Conditions Studied
Interventions
- DRUG CTLA4Ig / Abatacept
Study Locations (10)
California
- Local Institution - San Diego
Illinois
- Local Institution - Chicago
Massachusetts
- Local Institution - Boston
Michigan
- Local Institution - Ann Arbor
New Jersey
- Local Institution - New Brunswick
Oregon
- Local Institution - Portland
Pennsylvania
- Local Institution - Philadelphia
Texas
- Local Institution - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 1997-03 |
| Est. Completion | 1998-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00287547
The ClinicalTrials.gov registry entry for NCT00287547 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 68-participant average among 6 other Psoriasis Vulgaris trials with a reported enrollment target (112% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis Vulgaris appearing as the primary indexed condition, and to 1 intervention - of which CTLA4Ig / Abatacept is the first listed.
NCT00287547 reports 10 study locations spanning 10 distinct geographic areas - top geographies include California, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00287547 about?
NCT00287547 is a clinical study titled "Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris". The purpose of this study is to assess the safety, pharmacokinetics and clinical activity and immunogenicity of BMS-188667 (CTLA4Ig) in subjects with psoriasis vulgaris
What is the current status of trial NCT00287547?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 144 participants. The study started on 1997-03. Estimated completion is 1998-01.
What conditions does trial NCT00287547 study?
This clinical trial studies the following conditions: Psoriasis Vulgaris.
What interventions are being tested in trial NCT00287547?
The interventions under investigation include: CTLA4Ig / Abatacept (DRUG).
Who is sponsoring clinical trial NCT00287547?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00287547 being conducted?
This trial has 10 study locations across California, Illinois, Massachusetts, Michigan, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
COMPLETED · Phase 2
-
Correction of Psoriatic T Cell Signatures by Deucravacitinib
RECRUITING · Phase 4
-
Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III)
RECRUITING · Phase 3
-
Use of Botulinum Toxin to Treat Psoriasis
COMPLETED · Phase 1
-
Blue Light Phototherapy
COMPLETED · NA
-
A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis Vulgaris
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.